ZAKI LABABIDI, M.D., F.A.C.C DIPLOMATE, CARDIOVASCULAR DISEASES 3505 S. Mercy Road Gilbert, AZ 85297

POSITIONS January 2011 – Current

Director, Echocardiography Department Mercy Gilbert Medical Center Gilbert, AZ

May 2009 – Current

Interventional Cardiologist & President Fountain Hills Cardiovascular Center Fountain Hills, AZ

February 2009 – Current

Interventional Cardiologist & President Gilbert Cardiology Gilbert, AZ

April 2008 – Current

Clinical Assistant Professor Midwestern University Glendale, AZ

February 2007 – February 2009

Interventional Cardiologist & Clinical Director Cardiovascular & Stem Cell Consultants Gilbert, AZ

July 1, 2005 – January 2007:

Interventional Cardiologist Gene & Cell Department Arizona Heart Institute Phoenix, AZ

July 1, 2004 – June 30, 2005:

Interventional Cardiology Fellow Arizona Heart Institute Phoenix, AZ

August 1, 2004 – June 30, 2004:

Director, Department of Cardiology Roseland Community Hospital Chicago, IL

May 1996 – June 1998:

Associate Director, C.C.U./G.S.U. Mercy Hospital and Medical Center Chicago, IL 1

Teaching Staff, Cardiology Mercy Hospital and Medical Center Chicago, IL July 1995 – June 2004:

Private Practice in Cardiovascular Disease Chicago, IL

EDUCATION & TRAINING July 1992 – June 1995:

Cardiology Fellowship at Marshall University Huntington, WV

July 1991 – June 1992:

Chief Resident, Department of Medicine Mercy Hospital and Medical Center Chicago, IL

1988 – 1989:

Advanced Courses in Molecular Biology in Preparation for Master Degree at Marshall University Graduate School for Basic Medical Science Huntington, WV

1987 – 1988:

New Diagnostic Techniques for Coronary Artery Disease Postdoctoral Research, Department of Pathology University of Illinois, Chicago, IL

1986 – 1987:

Completing F.M.E.M.S. and Flex Examinations

1985 – 1986:

Emergency Room Physician Al-Ghazali Hospital Damascus, Syria

1979 – 1985:

Medical Student Damascus University School of Medicine Damascus, Syria

BOARDS & CERTIFICATES November 1995:

Board Certification in Cardiovascular Diseases

December 2005:

Board Recertification in Cardiovascular Diseases 2

October 2003:

Arizona State Medical Licensure

September 1992:

Board Certification in Internal Medicine

August 1991:

Illinois State Medical Licensure

June 1988:

Flex Certification

January 1987:

E.C.F.M.G. Certification

December 1985:

Syrian Medical Licensure

October 1985:

Medical Doctorate Diploma Damascus University School of Medicine

HOSPITALS & AFFILIATIONS Gilbert Cardiology 3505 S. Mercy Rd. Gilbert, AZ 85297 Fountain Hills Cardiovascular Center 16838 E. Palisades Blvd. #A107 Fountain Hills, AZ 85268 Mercy Gilbert Medical Center 3555 S. Val Vista Dr. Gilbert, AZ 85297 Chandler Regional Medical Center 475 S. Dobson Rd. Chandler, AZ 85224 Arizona Heart Hospital 1930 E. Thomas Rd. Phoenix, AZ 85016 Scottsdale Shea Medical Center 9003 E. Shea Blvd Scottsdale, AZ 85260 RESEARCH PROJECTS

3

MARVEL - A Phase II/III, Double-Blind, Randomized, Controlled, Multicenter Study to Assess the Safety and Cardiovascular Effects of Myocell(tm) Implantation by a Catheter Delivery System in Congestive Heart Failure Patients Post Myocardial Infarction(s) CVBT-CHD-7-01 Human Recombinant Fibroblast Growth Factor-1 (FGF-1141), for the Treatment of Subjects with Severe Coronary Heart Disease. A Double-blind, Placebo-controlled, Dose-varying Study CORAL - Cardiovascular Outcomes in Renal Atherosclerotic Lesions Randomized and MultiCenter Two-Group Clinical Trial To Assess The Best Treatment for patients with High Blood Pressure and Renal Artery Stenosis: Stenting with Anti-Hypertensive Medical Therapy HeartAware/Genomics - Defining the Relationship between Framingham Risk Score and Genetic Risk PROTECT II - A prospective, multi-center, randomized, controlled trial of the IMPELLA RECOVER LF 2.5 System versus Intra Aortic Balloon Pump in Patients Undergoing Non-emergent High Risk PCI TRACER - A Multi-center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficiency of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome FREEDOM – Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease Corautus VEGF-2 – Corautus Genetics, Inc., “A Multicenter, Randomized, Double-Blind, Dose Ranging Placebo-Controlled Study Evaluating Defined Doses of Percutaneously Delivered via Boston Scientific Stiletto Endocardial Direct Injection Catheter System pVGI. 1 (VEGF2) (placebo, 20, 200 or 800 g) In patients with Class III or IV Angina” Berlex – A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ad5FGF-4 in Patients with Stable Anginal; BB-IND #7471 Autologous Myoblast Transplantation for the Treatment of Infarcted Myocardium – A Pilot Study; IND 8776 A Phase 1 Study of Intracardiac Injection of Autogolous Myoblasts into Transmural Scar – Protocol IIAM02-3 BB-IND- 11611: A Randomized Pilot Study to Assess the Safety and Feasibility of Transplanting Autologous Skeletal Myoblasts, into Ischemic Myocardium, Using the Biosense Intra-Myocardial Injection and Mapping System

4

Baxter – A Double-blind, prospective, randomized, placebo-controlled study to determine the tolerability, efficacy, safety, and dose range of intramyocardial injections of auto-CD34+ cells for reduction of angina episodes in patients with refractory chronic myocardial ischemia. Osiris 401/402 – A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Multi-center Study to Determine the Safety of Intravenous Ex-Vivo Cultured Adult Human Mesenchymal Cells (Provacel ) Following Acute Myocardial Infarction SPIRIT III – Guidant Corporation, “SPIRIT III: A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects with de novo Native Coronary Artery Lesions” Protocol 03-360 Version 3.0, Dated February 14, 2005 AMEthyst – The Assessment of the Medtronic AVE Interceptor Saaphenous Vein Graft Filter System Transesophageal echocardiogram study to examine risk factor for stroke, including: spontaneous echo contrast in atrial fibrillation patients, aortic plaques and blood viscosity New diagnostic techniques to study coronary artery disease in humans Institution study to determine the correlation between thallium stress studies and the angiographic findings, department of cardiology, Marshall University

5